<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35149146</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-1899</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>58</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biotechnology advances</Title>
          <ISOAbbreviation>Biotechnol Adv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Better by design: What to expect from novel CAR-engineered cell therapies?</ArticleTitle>
        <Pagination>
          <StartPage>107917</StartPage>
          <MedlinePgn>107917</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biotechadv.2022.107917</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0734-9750(22)00013-1</ELocationID>
        <Abstract>
          <AbstractText>Chimeric antigen receptor (CAR) technology, and CAR-T cells in particular, have emerged as a new and powerful tool in cancer immunotherapy since demonstrating efficacy against several hematological malignancies. However, despite encouraging clinical results of CAR-T cell therapy products, a significant proportion of patients do not achieve satisfactory responses, or relapse. In addition, CAR-T cell applications to solid tumors is still limited due to the tumor microenvironment and lack of specifically targetable tumor antigens. All current products on the market, as well as most investigational CAR-T cell therapies, are autologous, using the patient's own peripheral blood mononuclear cells as starting material to manufacture a patient-specific batch. Alternative cell sources are, therefore, under investigation (e.g. allogeneic cells from an at least partially human leukocyte antigen (HLA)-matched healthy donor, universal "third-party" cells from a non-HLA-matched donor, cord blood-derived cells, immortalized cell lines or cells differentiated from induced pluripotent stem cells). However, genetic modifications of CAR-engineered cells, bioprocesses used to expand cells, and improved supply chains are still complex and costly. To overcome drawbacks associated with CAR-T technologies, novel CAR designs have been used to genetically engineer cells derived from alpha beta (αβ) T cells, other immune cells such as natural killer (NK) cells, gamma delta (γδ) T cells, macrophages or dendritic cells. This review endeavours to trigger ideas on the next generation of CAR-engineered cell therapies beyond CAR-T cells and, thus, will enable effective, safe and affordable therapies for clinical management of cancer. To achieve this, we present a multidisciplinary overview, addressing a wide range of critical aspects: CAR design, development and manufacturing technologies, pharmacological concepts and clinical applications of CAR-engineered cell therapies. Each of these fields employs a large number of ground-breaking scientific advances, where coordinated and complex process and product development occur at their interfaces.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Luginbuehl</LastName>
            <ForeName>Vera</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Oncology, Cell &amp; Gene Therapy, Novartis Pharma Schweiz AG, Rotkreuz, Switzerland. Electronic address: vera.luginbuehl@novartis.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abraham</LastName>
            <ForeName>Eytan</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Personalized Medicine Lonza Pharma&amp;Biotech, Lonza Ltd., Walkersville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kovar</LastName>
            <ForeName>Karin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>daspool, Wädenswil, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flaaten</LastName>
            <ForeName>Richard</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Oncology, Cell &amp; Gene Therapy, Novartis Norge AS, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Müller</LastName>
            <ForeName>Antonia M S</ForeName>
            <Initials>AMS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biotechnol Adv</MedlineTA>
        <NlmUniqueID>8403708</NlmUniqueID>
        <ISSNLinking>0734-9750</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000076962">Receptors, Chimeric Antigen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016219" MajorTopicYN="N">Immunotherapy, Adoptive</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076962" MajorTopicYN="Y">Receptors, Chimeric Antigen</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Advanced manufacturing technologies</Keyword>
        <Keyword MajorTopicYN="N">CAR discovery and development</Keyword>
        <Keyword MajorTopicYN="N">CAR pharmacology</Keyword>
        <Keyword MajorTopicYN="N">CAR-T cell therapy</Keyword>
        <Keyword MajorTopicYN="N">Chimeric antigen receptor (CAR)</Keyword>
        <Keyword MajorTopicYN="N">Clinical trials</Keyword>
        <Keyword MajorTopicYN="N">Genetic Engineering</Keyword>
        <Keyword MajorTopicYN="N">Macrophages</Keyword>
        <Keyword MajorTopicYN="N">Natural killer cells</Keyword>
        <Keyword MajorTopicYN="N">cancer immunotherapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35149146</ArticleId>
        <ArticleId IdType="doi">10.1016/j.biotechadv.2022.107917</ArticleId>
        <ArticleId IdType="pii">S0734-9750(22)00013-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
